Vericel (VCEL) EPS (Weighted Average and Diluted) (2010 - 2026)
Vericel's (VCEL) quarterly EPS (Weighted Average and Diluted) came in at -$0.12 in Q1 2026, up 47.83% year-on-year from -$0.08 in Q1 2025, and down 126.67% quarter-over-quarter from $0.45 in Q4 2025.
Vericel (VCEL) EPS (Weighted Average and Diluted) (2010 - 2026) Analysis & Trends
Vericel has disclosed EPS (Weighted Average and Diluted) across 12 years of filings, most recently posting -$0.12 for Q1 2026.
- EPS (Weighted Average and Diluted) for Q1 2026 came in at -$0.12, up 47.83% year-over-year; the trailing twelve-month figure through Mar 2026 was $0.42 (up 950.0% YoY), and the FY2025 annual result was $0.32, up 60.0% from the prior year.
- EPS (Weighted Average and Diluted) came in at -$0.12 for Q1 2026 at Vericel, down from $0.45 in the prior quarter.
- In the past five years, EPS (Weighted Average and Diluted) ranged from a high of $0.45 in Q4 2025 to a low of -$0.23 in Q1 2025.
- The 5-year median for EPS (Weighted Average and Diluted) is -$0.08 (2023), against an average of -$0.0.
- Peak annual rise in EPS (Weighted Average and Diluted) reached 600.0% in 2025, while the deepest fall reached 187.5% in 2025.
- Vericel's EPS (Weighted Average and Diluted) stood at $0.13 in 2022, then jumped by 107.69% to $0.27 in 2023, then soared by 44.44% to $0.39 in 2024, then increased by 15.38% to $0.45 in 2025, then slumped by 126.67% to -$0.12 in 2026.
- The last three EPS (Weighted Average and Diluted) figures came in at -$0.12 (Q1 2026), $0.45 (Q4 2025), and $0.1 (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EPS (Weighted Avg. Diluted) (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 925,601.88 Bn | 925,601.85 Bn | - | - |
| 2 | Belite Bio | 58,560.00 Bn | 58,560.00 Bn | - | 0.68 |
| 3 | Quantum Biopharma | 17,284.41 Bn | 17,284.40 Bn | - | 3.06 |
| 4 | Legend Biotech | 2,809.00 Bn | 2,808.71 Bn | 242.10 Mn | 3,086.42 |
| 5 | Evaxion A | 1,334.43 Bn | 1,334.42 Bn | - | - |
| 6 | Akari Therapeutics | 1,312.27 Bn | 1,312.26 Bn | - | 0.00 |
| 7 | Psyence Biomedical | 212.16 Bn | 212.16 Bn | - | 0.00 |
| 8 | Vertex Pharmaceuticals | 114.83 Bn | 107.58 Bn | 2.59 Bn | 4.02 |
| 9 | Abivax | 91.96 Bn | 91.96 Bn | - | -0.61 |
| 10 | Vericel | 2.04 Bn | 1.90 Bn | 49.27 Mn | -0.12 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -0.12 |
| Dec 31, 2025 | 0.45 |
| Sep 30, 2025 | 0.10 |
| Jun 30, 2025 | -0.01 |
| Mar 31, 2025 | -0.23 |
| Dec 31, 2024 | 0.39 |
| Sep 30, 2024 | -0.02 |
| Jun 30, 2024 | -0.10 |
| Mar 31, 2024 | -0.08 |
| Dec 31, 2023 | 0.27 |
| Sep 30, 2023 | -0.08 |
| Jun 30, 2023 | -0.11 |
| Mar 31, 2023 | -0.16 |
| Dec 31, 2022 | 0.13 |
| Sep 30, 2022 | -0.14 |
| Jun 30, 2022 | -0.19 |
| Mar 31, 2022 | -0.15 |
| Dec 31, 2021 | 0.10 |
| Sep 30, 2021 | -0.11 |
| Jun 30, 2021 | -0.08 |